AB0156 The efficacy of alendronate in postmenopausical osteoporosis
Annals of the Rheumatic Diseases(2001)
摘要
Background This is a prospective study of bone mineral density in postmenopausical women treated with alendronate. Objectives To evaluate the efficacy of alendronate in postmenopausical osteoporotic women for 1, 2 and 3 years. Methods In a prospective study, we included 98 women diagnosed of postmenopausical osteoporosis attended from 1997 to 2000. The mean age was 59.07 (SD: 6.68). Patients received alendronate 10 mg daily, they were allowed to take calcium and vitamine D supplementation. The subjects were assessed at baseline, 12, 24 and 36 months for bone mineral density (BMD) measurements and X-ray and every 6 months blood and urinary biochemistries and markers of bone turnover were done. Results Sixteen patients (16%) have dropped out because of adverse effects, the most common was gastrointestinal events. 34 (34.6%) patients had previous fractures (17 had spine fractures, 12 Colles´s fractures and one hip fracture). Three patients on treatment with alendronate had new fractures (1 spine, 1 scaphoid and one Colles´s fracture). 70, 24 and 7 subjects have completed one, two and three years of treatment, respectively. The results were analysed by Student´s t-test. Patients treated with alendronate for 1 year had significantly greater improvement in BMD at spine. The mean BMD at baseline was 0.373 vs 0.773 (p Conclusion Patients treated with alendronate for one year had significantly greater improvement in BMD at both the spine and hip.
更多查看译文
关键词
osteoporosis,alendronate
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要